These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 16199428

  • 1. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance.
    Lemay A, Dodin S, Turcot L, Déchêne F, Forest JC.
    Hum Reprod; 2006 Jan; 21(1):121-8. PubMed ID: 16199428
    [Abstract] [Full Text] [Related]

  • 2. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
    Fruzzetti F, Perini D, Lazzarini V, Parrini D, Gambacciani M, Genazzani AR.
    Fertil Steril; 2010 Oct; 94(5):1793-8. PubMed ID: 19931080
    [Abstract] [Full Text] [Related]

  • 3. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J, Zhu Y, Jiang Y, Cao Y.
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [Abstract] [Full Text] [Related]

  • 4. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.
    Yilmaz M, Bukan N, Ayvaz G, Karakoç A, Törüner F, Cakir N, Arslan M.
    Hum Reprod; 2005 Dec; 20(12):3333-40. PubMed ID: 16123091
    [Abstract] [Full Text] [Related]

  • 5. A new association of ethinylestradiol (0.035 mg) cyproterone acetate (2 mg) in the therapy of polycystic ovary syndrome.
    Falsetti L, Dordoni D, Gastaldi C, Gastaldi A.
    Acta Eur Fertil; 1986 Dec; 17(1):19-25. PubMed ID: 2941960
    [Abstract] [Full Text] [Related]

  • 6. Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome.
    Uras R, Orrù M, Pani F, Marotto MF, Pilloni M, Guerriero S, Etzi R, Zedda P, Sorge R, Lello S, Melis GB, Paoletti AM.
    Contraception; 2010 Aug; 82(2):131-8. PubMed ID: 20654753
    [Abstract] [Full Text] [Related]

  • 7. Increased follistatin levels after oral contraceptive treatment in obese and non-obese women with polycystic ovary syndrome.
    Chen MJ, Yang WS, Chen HF, Kuo JJ, Ho HN, Yang YS, Chen SU.
    Hum Reprod; 2010 Mar; 25(3):779-85. PubMed ID: 20093255
    [Abstract] [Full Text] [Related]

  • 8. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.
    Ortega-González C, Cardoza L, Coutiño B, Hidalgo R, Arteaga-Troncoso G, Parra A.
    J Endocrinol; 2005 Jan; 184(1):233-9. PubMed ID: 15642799
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: a randomised controlled study.
    Karakurt F, Sahin I, Güler S, Demirbas B, Culha C, Serter R, Aral Y, Bavbek N.
    Adv Ther; 2008 Apr; 25(4):321-8. PubMed ID: 18389188
    [Abstract] [Full Text] [Related]

  • 10. Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome.
    Mitkov M, Pehlivanov B, Terzieva D.
    Eur J Obstet Gynecol Reprod Biol; 2005 Feb 01; 118(2):209-13. PubMed ID: 15653205
    [Abstract] [Full Text] [Related]

  • 11. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.
    Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE.
    Fertil Steril; 2004 Oct 01; 82(4):893-902. PubMed ID: 15482765
    [Abstract] [Full Text] [Related]

  • 12. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.
    Florakis D, Diamanti-Kandarakis E, Katsikis I, Nassis GP, Karkanaki A, Georgopoulos N, Panidis D.
    Int J Obes (Lond); 2008 Apr 01; 32(4):692-9. PubMed ID: 18071341
    [Abstract] [Full Text] [Related]

  • 13. [Endocrine and metabolic effects of metformin in combination with compound cyproterone acetate in women with polycystic ovarian syndrome].
    Ye BL, Yang HY, Zhao JZ, Lin JJ, Lin WQ.
    Zhonghua Fu Chan Ke Za Zhi; 2003 Dec 01; 38(12):745-8. PubMed ID: 14728846
    [Abstract] [Full Text] [Related]

  • 14. Experience in the long-term treatment of patients with hirsutism and/or acne with cyproterone acetate-containing preparations: efficacy, metabolic and endocrine effects.
    van Wayjen RG, van den Ende A.
    Exp Clin Endocrinol Diabetes; 1995 Dec 01; 103(4):241-51. PubMed ID: 7584530
    [Abstract] [Full Text] [Related]

  • 15. Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses.
    Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI, Sanchón R, San Millán JL, Escobar-Morreale HF.
    Diabetes Care; 2007 Sep 01; 30(9):2309-13. PubMed ID: 17536071
    [Abstract] [Full Text] [Related]

  • 16. Effects of two different oral contraceptives on homocysteine metabolism in women with polycystic ovary syndrome.
    Cagnacci A, Tirelli A, Renzi A, Paoletti AM, Volpe A.
    Contraception; 2006 Apr 01; 73(4):348-51. PubMed ID: 16531164
    [Abstract] [Full Text] [Related]

  • 17. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS.
    J Clin Endocrinol Metab; 2000 Sep 01; 85(9):3161-8. PubMed ID: 10999803
    [Abstract] [Full Text] [Related]

  • 18. Alteration of cardiovascular risk parameters in women with polycystic ovary syndrome who were prescribed to ethinyl estradiol-cyproterone acetate.
    Gode F, Karagoz C, Posaci C, Saatli B, Uysal D, Secil M, Akdeniz B.
    Arch Gynecol Obstet; 2011 Oct 01; 284(4):923-9. PubMed ID: 21140159
    [Abstract] [Full Text] [Related]

  • 19. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome.
    Meyer C, McGrath BP, Teede HJ.
    Diabetes Care; 2007 Mar 01; 30(3):471-8. PubMed ID: 17327307
    [Abstract] [Full Text] [Related]

  • 20. Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel.
    Cagnacci A, Paoletti AM, Renzi A, Orrù M, Pilloni M, Melis GB, Volpe A.
    J Clin Endocrinol Metab; 2003 Aug 01; 88(8):3621-5. PubMed ID: 12915645
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.